-
1دورية أكاديمية
المؤلفون: Whybra, Philip, Zwanenburg, Alex, Andrearczyk, Vincent, Schaer, Roger, Apte, Aditya P., Ayotte, Alexandre, Baheti, Bhakti, Bakas, Spyridon, Bettinelli, Andrea, Boellaard, Ronald, Boldrini, Luca, Buvat, Irène, Cook, Gary J. R., Dietsche, Florian, Dinapoli, Nicola, Gabryś, Hubert S., Goh, Vicky, Guckenberger, Matthias, Hatt, Mathieu, Hosseinzadeh, Mahdi, Iyer, Aditi, Lenkowicz, Jacopo, Loutfi, Mahdi A. L., Löck, Steffen, Marturano, Francesca, Morin, Olivier, Nioche, Christophe, Orlhac, Fanny, Pati, Sarthak, Rahmim, Arman, Rezaeijo, Seyed Masoud, Rookyard, Christopher G., Salmanpour, Mohammad R., Schindele, Andreas, Shiri, Isaac, Spezi, Emiliano, Tanadini-Lang, Stephanie, Tixier, Florent, Upadhaya, Taman, Valentini, Vincenzo, van Griethuysen, Joost J. M., Yousefirizi, Fereshteh, Zaidi, Habib, Müller, Henning, Vallières, Martin, Depeursinge, Adrien
الوصف: Standardizing convolutional filters that enhance specific structures and patterns in medical imaging enables reproducible radiomics analyses, improving consistency and reliability for enhanced clinical insights. Filters are commonly used to enhance specific structures and patterns in images, such as vessels or peritumoral regions, to enable clinical insights beyond the visible image using radiomics. However, their lack of standardization restricts reproducibility and clinical translation of radiomics decision support tools. In this special report, teams of researchers who developed radiomics software participated in a three-phase study (September 2020 to December 2022) to establish a standardized set of filters. The first two phases focused on finding reference filtered images and reference feature values for commonly used convolutional filters: mean, Laplacian of Gaussian, Laws and Gabor kernels, separable and nonseparable wavelets (including decomposed forms), and Riesz transformations. In the first phase, 15 teams used digital phantoms to establish 33 reference filtered images of 36 filter configurations. In phase 2, 11 teams used a chest CT image to derive reference values for 323 of 396 features computed from filtered images using 22 filter and image processing configurations. Reference filtered images and feature values for Riesz transformations were not established. Reproducibility of standardized convolutional filters was validated on a public data set of multimodal imaging (CT, fluorodeoxyglucose PET, and T1-weighted MRI) in 51 patients with soft-tissue sarcoma. At validation, reproducibility of 486 features computed from filtered images using nine configurations × three imaging modalities was assessed using the lower bounds of 95% CIs of intraclass correlation coefficients. Out of 486 features, 458 were found to be reproducible across nine teams with lower bounds of 95% CIs of intraclass correlation coefficients greater than 0.75. In conclusion, eight filter types were standardized with reference ...
وصف الملف: application/pdf
العلاقة: https://orca.cardiff.ac.uk/id/eprint/166232/1/IBSI2_manuscript.pdfTest; Whybra, Philip https://orca.cardiff.ac.uk/view/cardiffauthors/A281616W.htmlTest, Zwanenburg, Alex, Andrearczyk, Vincent, Schaer, Roger, Apte, Aditya P., Ayotte, Alexandre, Baheti, Bhakti, Bakas, Spyridon, Bettinelli, Andrea, Boellaard, Ronald, Boldrini, Luca, Buvat, Irène, Cook, Gary J. R., Dietsche, Florian, Dinapoli, Nicola, Gabryś, Hubert S., Goh, Vicky, Guckenberger, Matthias, Hatt, Mathieu, Hosseinzadeh, Mahdi, Iyer, Aditi, Lenkowicz, Jacopo, Loutfi, Mahdi A. L., Löck, Steffen, Marturano, Francesca, Morin, Olivier, Nioche, Christophe, Orlhac, Fanny, Pati, Sarthak, Rahmim, Arman, Rezaeijo, Seyed Masoud, Rookyard, Christopher G., Salmanpour, Mohammad R., Schindele, Andreas, Shiri, Isaac, Spezi, Emiliano https://orca.cardiff.ac.uk/view/cardiffauthors/A0624402.htmlTest orcid:0000-0002-1452-8813 orcid:0000-0002-1452-8813, Tanadini-Lang, Stephanie, Tixier, Florent, Upadhaya, Taman, Valentini, Vincenzo, van Griethuysen, Joost J. M., Yousefirizi, Fereshteh, Zaidi, Habib, Müller, Henning, Vallières, Martin and Depeursinge, Adrien 2024. The image biomarker standardization initiative: Standardized convolutional filters for reproducible radiomics and enhanced clinical insights. Radiology 310 (2) 10.1148/radiol.231319 https://doi.org/10.1148/radiol.231319Test file https://orca.cardiff.ac.uk/id/eprint/166232/1/IBSI2_manuscript.pdfTest
الإتاحة: https://doi.org/10.1148/radiol.231319Test
https://orca.cardiff.ac.uk/id/eprint/166232Test/
https://orca.cardiff.ac.uk/id/eprint/166232/1/IBSI2_manuscript.pdfTest -
2دورية أكاديمية
المؤلفون: Sharkey, Amy R, Koglin, Norman, Mittra, Erik S, Han, Sangwon, Cook, Gary J R, Witney, Timothy H
المصدر: Sharkey , A R , Koglin , N , Mittra , E S , Han , S , Cook , G J R & Witney , T H 2024 , ' Clinical [18F]FSPG Positron Emission Tomography Imaging Reveals Heterogeneity in Tumor-Associated System xc- Activity ' , Cancers , vol. 16 , no. 7 , 1437 . https://doi.org/10.3390/cancers16071437Test
الوصف: BACKGROUND: (4 S)-4-(3-[18F]fluoropropyl)-L-glutamic acid ([18F]FSPG) positron emission tomography/computed tomography (PET/CT) provides a readout of system xc- transport activity and has been used for cancer detection in clinical studies of different cancer types. As system xc- provides the rate-limiting precursor for glutathione biosynthesis, an abundant antioxidant, [18F]FSPG imaging may additionally provide important prognostic information. Here, we performed an analysis of [18F]FSPG radiotracer distribution between primary tumors, metastases, and normal organs from cancer patients. We further assessed the heterogeneity of [ 18F]FSPG retention between cancer types, and between and within individuals. METHODS: This retrospective analysis of prospectively collected data compared [18F]FSPG PET/CT in subjects with head and neck squamous cell cancer (HNSCC, n = 5) and non-small-cell lung cancer (NSCLC, n = 10), scanned at different institutions. Using semi-automated regions of interest drawn around tumors and metastases, the maximum standardized uptake value (SUV max), SUV mean, SUV standard deviation and SUV peak were measured. [18F]FSPG time-activity curves (TACs) for normal organs, primary tumors and metastases were subsequently compared to 18F-2-fluoro-2-deoxy-D-glucose ([18F]FDG) PET/CT at 60 min post injection (p.i.). RESULTS: The mean administered activity of [18F]FSPG was 309.3 ± 9.1 MBq in subjects with NSCLC and 285.1 ± 11.3 MBq in those with HNSCC. The biodistribution of [18F]FSPG in both cohorts showed similar TACs in healthy organs from cancer patients. There was no statistically significant overall difference in the average SUV max of tumor lesions at 60 min p.i. for NSCLC (8.1 ± 7.1) compared to HNSCC (6.0 ± 4.1; p = 0.29) for [18F]FSPG. However, there was heterogeneous retention between and within cancer types; the SUV max at 60 min p.i. ranged from 1.4 to 23.7 in NSCLC and 3.1-12.1 in HNSCC. CONCLUSION: [18F]FSPG PET/CT imaging from both NSCLC and HNSCC cohorts showed the same normal-tissue ...
الإتاحة: https://doi.org/10.3390/cancers16071437Test
https://kclpure.kcl.ac.uk/portal/en/publications/4a47f769-dd12-4ab5-bf56-8bbe733486fbTest
http://www.scopus.com/inward/record.url?scp=85190137342&partnerID=8YFLogxKTest -
3دورية أكاديمية
المؤلفون: Puri, Tanuj, Frost, Michelle L., Moore, Amelia E. B., Choudhury, Ananya, Vinjamuri, Sobhan, Mahajan, Abhishek, Fynbo, Claire, Vrist, Marie, Theil, Jørn, Kairemo, Kalevi, Wong, James, Zaidi, Habib, Revheim, Mona-Elisabeth, Werner, Thomas J., Alavi, Abass, Cook, Gary J. R., Blake, Glen M.
المصدر: ISSN: 1664-2392 ; Frontiers in endocrinology, vol. 14 (2023) 1236881.
مصطلحات موضوعية: info:eu-repo/classification/ddc/616.0757, Quantitative measurement of bone, Bone metabolic flux, Clinical applications, Future developments, [18F]NaF, Ki, PET-CT, [18F] sodium fluoride, Bone Neoplasms, Bone and Bones / diagnostic imaging, Humans, Positron Emission Tomography Computed Tomography / methods, Positron-Emission Tomography / methods, Sodium Fluoride
الوصف: We review the rationale, methodology, and clinical utility of quantitative [ 18 F] sodium fluoride ([ 18 F]NaF) positron emission tomography-computed tomography (PET-CT) imaging to measure bone metabolic flux (K i , also known as bone plasma clearance), a measurement indicative of the local rate of bone formation at the chosen region of interest. We review the bone remodelling cycle and explain what aspects of bone remodelling are addressed by [ 18 F]NaF PET-CT. We explain how the technique works, what measurements are involved, and what makes [ 18 F]NaF PET-CT a useful tool for the study of bone remodelling. We discuss how these measurements can be simplified without loss of accuracy to make the technique more accessible. Finally, we briefly review some key clinical applications and discuss the potential for future developments. We hope that the simplified method described here will assist in promoting the wider use of the technique.
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37780613; https://archive-ouverte.unige.ch/unige:174983Test; unige:174983
-
4دورية أكاديمية
المؤلفون: Papa, Sophie, Adami, Antonella, Metoudi, Michael, Beatson, Richard, George, Molly Sarah, Achkova, Daniela, Williams, Evangelia, Arif, Sefina, Reid, Fiona, Elstad, Maria, Beckley-Hoelscher, Nicholas, Douri, Abdel, Delord, Marc, Lyne, Mike, Shivapatham, Dharshene, Fisher, Christopher, Hope, Andrew, Gooljar, Sakina, Mitra, Arindam, Gomm, Linda, Morton, Cienne, Henley-Smith, Rhonda, Thavaraj, Selvam, Santambrogio, Alice, Andoniadou, Cynthia, Allen, Sarah, Gibson, Victoria, Cook, Gary J R, Parente-Pereira, Ana C, Davies, David M, Farzaneh, Farzin, Schurich, Anna, Guerrero-Urbano, Teresa, Jeannon, Jean-Pierre, Spicer, James, Maher, John
المصدر: Papa , S , Adami , A , Metoudi , M , Beatson , R , George , M S , Achkova , D , Williams , E , Arif , S , Reid , F , Elstad , M , Beckley-Hoelscher , N , Douri , A , Delord , M , Lyne , M , Shivapatham , D , Fisher , C , Hope , A , Gooljar , S , Mitra , A , Gomm , L , Morton , C , Henley-Smith , R , Thavaraj , S , Santambrogio , A , Andoniadou , ....
الوصف: Background: Locally advanced/recurrent head and neck squamous cell carcinoma (HNSCC) is associated with significant morbidity and mortality. To target upregulated ErbB dimer expression in this cancer, we developed an autologous CD28-based chimeric antigen receptor T-cell (CAR-T) approach named T4 immunotherapy. Patient-derived T-cells are engineered by retroviral transduction to coexpress a panErbB-specific CAR called T1E28ζ and an IL-4-responsive chimeric cytokine receptor, 4αβ, which allows IL-4-mediated enrichment of transduced cells during manufacture. These cells elicit preclinical antitumor activity against HNSCC and other carcinomas. In this trial, we used intratumoral delivery to mitigate significant clinical risk of on-target off-tumor toxicity owing to low-level ErbB expression in healthy tissues. Methods: We undertook a phase 1 dose-escalation 3+3 trial of intratumoral T4 immunotherapy in HNSCC (NCT01818323). CAR T-cell batches were manufactured from 40 to 130 mL of whole blood using a 2-week semiclosed process. A single CAR T-cell treatment, formulated as a fresh product in 1-4 mL of medium, was injected into one or more target lesions. Dose of CAR T-cells was escalated in 5 cohorts from 1×10 7 -1×10 9 T4 + T-cells, administered without prior lymphodepletion. Results: Despite baseline lymphopenia in most enrolled subjects, the target cell dose was successfully manufactured in all cases, yielding up to 7.5 billion T-cells (67.5±11.8% transduced), without any batch failures. Treatment-related adverse events were all grade 2 or less, with no dose-limiting toxicities (Common Terminology Criteria for Adverse Events V.4.0). Frequent treatment-related adverse events were tumor swelling, pain, pyrexias, chills, and fatigue. There was no evidence of leakage of T4 + T-cells into the circulation following intratumoral delivery, and injection of radiolabeled cells demonstrated intratumoral persistence. Despite rapid progression at trial entry, stabilization of disease (Response Evaluation Criteria in Solid ...
الإتاحة: https://doi.org/10.1136/jitc-2023-007162Test
https://kclpure.kcl.ac.uk/portal/en/publications/9572ca73-d6ea-4d1d-8862-ea9fd48284ceTest
https://jitc.bmj.com/content/11/6/e007162Test
http://www.scopus.com/inward/record.url?scp=85163903407&partnerID=8YFLogxKTest -
5دورية أكاديمية
المؤلفون: Sharkey, Amy R, Witney, Timothy H, Cook, Gary J R
المصدر: Sharkey , A R , Witney , T H & Cook , G J R 2023 , ' Is System x c - a Suitable Target for Tumour Detection and Response Assessment with Imaging? ' , Cancers , vol. 15 , no. 23 , 5573 . https://doi.org/10.3390/cancers15235573Test
الوصف: System xc- is upregulated in cancer cells and can be imaged using novel radiotracers, most commonly with (4S)-4-(3-[ 18F]fluoropropyl)-L-glutamic acid (18F-FSPG). The aim of this review was to summarise the use of 18F-FSPG in humans, explore the benefits and limitations of 18F-FSPG, and assess the potential for further use of 18F-FSPG in cancer patients. To date, ten papers have described the use of 18F-FSPG in human cancers. These studies involved small numbers of patients (range 1-26) and assessed the use of 18F-FSPG as a general oncological diagnostic agent across different cancer types. These clinical trials were contrasting in their findings, limiting the scope of 18F-FSPG PET/CT as a purely diagnostic agent, primarily due to heterogeneity of 18F-FSPG retention both between cancer types and patients. Despite these limitations, a potential further application for 18F-FSPG is in the assessment of early treatment response and prediction of treatment resistance. Animal models of cancer have shown that changes in 18F-FSPG retention following effective therapy precede glycolytic changes, as indicated by 18F-FDG, and changes in tumour volume, as measured by CT. If these results could be replicated in human clinical trials, imaging with 18F-FSPG PET/CT would offer an exciting route towards addressing the currently unmet clinical needs of treatment resistance prediction and early imaging assessment of therapy response.
الإتاحة: https://doi.org/10.3390/cancers15235573Test
https://kclpure.kcl.ac.uk/portal/en/publications/af909049-f541-447c-a2ff-5a1a2ae3d16cTest
http://www.scopus.com/inward/record.url?scp=85179369397&partnerID=8YFLogxKTest -
6دورية أكاديمية
المؤلفون: Cobb, Robert, Cook, Gary J. R., Reader, Andrew J.
المصدر: Cobb , R , Cook , G J R & Reader , A J 2023 , ' Deep Learned Segmentations of Inflammation for Novel ⁹⁹ᵐTc -maraciclatide Imaging of Rheumatoid Arthritis ' , Diagnostics (Basel, Switzerland) . < https://www.mdpi.com/2075-4418/13/21/3298Test >
الوصف: Rheumatoid arthritis (RA) is an autoimmune disease that causes joint pain, stiffness, and erosion. Power Doppler ultrasound and MRI are imaging modalities used in detecting and monitoring the disease, but they have limitations. ⁹⁹mTc-maraciclatide gamma camera imaging is a novel technique that can detect joint inflammation at all sites in a single examination and has been shown to correlate with power Doppler ultrasound. In this work, we investigate if machine learning models can be used to automatically segment regions of normal, low, and highly inflamed tissue from 192 ⁹⁹mTc-maraciclatide scans of the hands and wrists from 48 patients. Two models were trained: a thresholding model that learns lower and upper threshold values and a neural-network-based nnU-Net model that uses a convolutional neural network (CNN). The nnU-Net model showed 0.94 ± 0.01, 0.51 ± 0.14, and 0.76 ± 0.16 modified Dice scores for segmenting the normal, low, and highly inflamed tissue, respectively, when compared to clinical segmented labels. This outperforms the thresholding model, which achieved modified Dice scores of 0.92 ± 0.01, 0.14 ± 0.07, and 0.35 ± 0.21, respectively. This is an important first step in developing artificial intelligence (AI) tools to assist clinicians’ workflow in the use of this new radiopharmaceutical.
-
7دورية أكاديمية
المؤلفون: Withey, Samuel J., Owczarczyk, Kasia, Grzeda, Mariusz, Yip, Connie, Deere, Harriet, Green, Mike, Maisey, Nick, Davies, Andrew, Cook, Gary J., Goh, Vicky, Subesinghe, Manil
المصدر: Withey , S J , Owczarczyk , K , Grzeda , M , Yip , C , Deere , H , Green , M , Maisey , N , Davies , A , Cook , G J , Goh , V & Subesinghe , M 2023 , ' Association of Dynamic Contrast-Enhanced MRI and 18F-Fluorodeoxyglucose PET/CT Parameters with Neoadjuvant Therapy Response and Survival in Esophagogastric Cancer ' , European Journal of Surgical Oncology , vol. 49 , no. 10 , 106934 . https://doi.org/10.1016Test/j.ejso.2023.05.009
الوصف: Introduction Better predictive markers are needed to deliver individualized care for patients with primary esophagogastric cancer. This exploratory study aimed to assess whether pre-treatment imaging parameters from dynamic contrast-enhanced MRI and 18F-fluorodeoxyglucose (18F-FDG) PET/CT are associated with response to neoadjuvant therapy or outcome. Materials and methods Following ethical approval and informed consent, prospective participants underwent dynamic contrast-enhanced MRI and 18F-FDG PET/CT prior to neoadjuvant chemotherapy/chemoradiotherapy ± surgery. Vascular dynamic contrast-enhanced MRI and metabolic 18F-FDG PET parameters were compared by tumor characteristics using Mann Whitney U test and with pathological response (Mandard tumor regression grade), recurrence-free and overall survival using logistic regression modelling, adjusting for predefined clinical variables. Results 39 of 47 recruited participants (30 males; median age 65 years, IQR: 54, 72 years) were included in the final analysis. The tumor vascular-metabolic ratio was higher in patients remaining node positive following neoadjuvant therapy (median tumor peak enhancement/SUVmax ratio: 0.052 vs. 0.023, p = 0.02). In multivariable analysis adjusted for age, gender, pre-treatment tumor and nodal stage, peak enhancement (highest gadolinium concentration value prior to contrast washout) was associated with pathological tumor regression grade. The odds of response decreased by 5% for each 0.01 unit increase (OR 0.95; 95% CI: 0.90, 1.00, p = 0.04). No 18F-FDG PET/CT parameters were predictive of pathological tumor response. No relationships between pre-treatment imaging and survival were identified. Conclusion Pre-treatment esophagogastric tumor vascular and metabolic parameters may provide additional information in assessing response to neoadjuvant therapy.
الإتاحة: https://doi.org/10.1016Test/j.ejso.2023.05.009
https://kclpure.kcl.ac.uk/portal/en/publications/5d1e47a2-3148-4750-a70b-d628ab07907fTest
http://www.scopus.com/inward/record.url?scp=85159040784&partnerID=8YFLogxKTest -
8دورية أكاديمية
المصدر: Puri , T , Frost , M L , Moore , A E B , Cook , G J R & Blake , G M 2023 , ' Input function and modeling for determining bone metabolic flux using [18 F] sodium fluoride PET imaging: a step-by-step guide ' , Medical Physics , vol. 50 , no. 4 , pp. 2071-2088 . https://doi.org/10.1002/mp.16125Test
مصطلحات موضوعية: PET imaging, [18F] Sodium Fluoride, Arterial Input Function, Modeling, Bone Metabolism, ResearchInstitutes_Networks_Beacons/mcrc, Manchester Cancer Research Centre
الوصف: Studies of skeletal metabolism using measurements of bone metabolic flux (Ki) obtained with [18F] sodium fluoride ([18F]NaF) positron emission tomography (PET) scans have been used in clinical research for the last 30 years. The technique has proven useful as an imaging biomarker in trials of novel drug treatments for osteoporosis and investigating other metabolic bone diseases, including chronic kidney disease mineral and bone disorder. It has also been shown to be valuable in metastatic bone disease in breast cancer patients and may have potential in other cancer types, such as prostate cancer, to assess early bone fracture risk. However, these studies have usually required a 60-min dynamic PET scan and measurement of the arterial input function (AIF), making them difficult to translate into the clinic for diagnostic purposes. We have previously proposed a simplified method that estimates the Ki value at an imaging site from a short (4-min) static scan and venous blood samples. A key advantage of this method is that, by acquiring a series of static scans, values of Ki can be quickly measured at multiple sites using a single injection of the tracer. To date, the widespread use of [18F]NaF PET has been limited by the need to measure the AIF required for the mathematical modeling of tracer kinetics to derive Ki and other kinetic parameters. In this report, we review different methods of measuring the AIF, including direct arterial sampling, the use of a semi-population input function (SP-AIF), and image-derived input function, the latter two requiring only two or three venous blood samples obtained between 30 and 60 min after injection. We provide an SP-AIF model and a spreadsheet for calculating Ki values using the static scan method that others can use to study bone metabolism in metabolic and metastatic bone diseases without requiring invasive arterial blood sampling. The method shortens scan times, simplifies procedures and reduces the cost of multi-center trials without losing accuracy or precision.
الإتاحة: https://doi.org/10.1002/mp.16125Test
https://research.manchester.ac.uk/en/publications/778edf4e-8c1a-4b7f-8654-c3f899b9dd89Test
https://aapm.onlinelibrary.wiley.com/hub/journal/24734209/video-galleryTest -
9دورية أكاديمية
المؤلفون: Hughes, Daniel Johnathan, Chand, Gitasha, Johnson, Jessica, Bailey, Damion, Adamson, Kathryn, Goh, Vicky, Cook, Gary J. R.
المساهمون: Cancer Research UK, Wellcome Trust
المصدر: EJNMMI Research ; volume 13, issue 1 ; ISSN 2191-219X
مصطلحات موضوعية: Radiology, Nuclear Medicine and imaging
الوصف: Background Immune checkpoint inhibitors, including those against programmed cell death protein-1 (PD-1) or its ligand (PD-L1), are routinely used to treat non-small cell lung cancer (NSCLC). PD-L1 is a validated prognostic and predictive immunohistochemical biomarker of anti-PD-1/PD-L1 therapy but displays temporospatial heterogeneity of expression. Non-invasive radiopharmaceutical techniques, including technetium-99m [ 99m Tc]-labelled anti-PD-L1 single-domain antibody (NM-01) SPECT/CT, have the potential to improve the predictive value of PD-L1 assessment. This study aims to determine the inter- and intra-rater agreement of the quantitative measurement of [ 99m Tc]NM-01 SPECT/CT in NSCLC. Methods Participants ( n = 14) with untreated advanced NSCLC underwent [ 99m Tc]NM-01 SPECT/CT at baseline ( n = 3) or at baseline plus 9-week follow-up ( n = 11). [ 99m Tc]NM-01 uptake (of primary lung, lymph node, thoracic and distant metastases, and healthy reference tissues) was measured using SUV max and malignant lesion-to-blood pool ratios with Siemens xSPECT Broad Quantification software by three independent raters. Intraclass correlation coefficients (ICC) were calculated and Bland–Altman plot analysis performed to determine inter- and intra-rater agreement. Results There was excellent inter-rater agreement of manual freehand SUV max scores of primary lung tumour (T; n = 25; ICC 1.00; 95% CI 0.99–1.00), individual lymph node metastases (LN; n = 56; ICC 0.97; 95% CI 0.95–0.98), thoracic metastases (ThMet; n = 9; ICC 0.94; 95% CI 0.83–0.99) and distant metastases (DisMet; n = 21; ICC 0.91; 95% CI 0.83–0.96). The inter-rater ICCs of tumour-to-blood pool (T:BP), LN:BP, ThMet:BP and DisMet:BP measures of [ 99m Tc]NM-01 uptake also demonstrated good or excellent agreement. Manual freehand scoring of T, LN, ThMet, DisMet and their ratios using [ 99m Tc]NM-01 SPECT/CT following a 28-day interval was consistent for all raters with good or excellent intra-rater agreement demonstrated (ICCs range 0.86–1.00). Conclusion ...
-
10دورية أكاديمية
المؤلفون: Nazir, Muhummad Sohaib, Hughes, Daniel Johnathan, Chand, Gitasha, Adamson, Kathryn, Johnson, Jessica, Bailey, Damion, Gibson, Victoria, Ting, Hong Hoi, Lyon, Alexander R., Cook, Gary J. R., Edmonds, Scott, Georgiou, Alexandros, Karapanagiotou, Eleni, Josephs, Debra, McLean, Emma, Spicer, James, Goh, Vicky
المساهمون: National Institute for Health Research Health Protection Research Unit
المصدر: EJNMMI Research ; volume 13, issue 1 ; ISSN 2191-219X
مصطلحات موضوعية: Radiology, Nuclear Medicine and imaging
الوصف: Background Myocardial programmed death-ligand 1 (PD-L1) expression is implicated in immune checkpoint inhibitor (ICI)-associated myocarditis. Measurement of myocardial PD-L1 expression may have potential use as a mechanistic and predictive biomarker. The aim of this study was to determine non-invasive assessment of myocardial PD-L1 expression using [ 99m Tc]-labelled anti-PD-L1 single-domain antibody (NM-01) SPECT/CT. Methods Thoracic [ 99m Tc]NM-01 SPECT/CT was performed in lung cancer patients ( n = 10) at baseline and 9-weeks following anti-programmed cell death protein 1 (PD-1) therapy. Baseline and 9-week left ventricular and right ventricular to blood pool ratios (LV max :BP) and (RV max :BP) were measured. LV max was compared to background skeletal muscle (muscle max ). Intra-rater reliability was determined by intraclass correlation coefficient (ICC) and Bland–Altman analysis. Results Mean LV max :BP values were 2.76 ± 0.67 at baseline vs 2.55 ± 0.77 at 9 weeks ( p = 0.42). Mean RV max :BP was 1.82 ± 0.32 at baseline vs 1.76 ± 0.45 at 9 weeks ( p = 0.67). Myocardial PD-L1 expression was at least threefold greater than skeletal muscle at baseline for the LV (LV max to muscle max 3.71 ± 0.77 vs 0.98 ± 0.20 ( p < 0.001)) and at least twofold for the RV (LV max to muscle max 2.49 ± 0.63 vs 0.98 ± 0.20 ( p < 0.001)). There was excellent intra-rater reliability for LV max :BP with ICC 0.99 (95% confidence interval 0.94–0.99, p < 0.001), mean bias -0.05 ± 0.14 (95% limits of agreement -0.32 to 0.21). There were no major adverse cardiovascular events or myocarditis during follow-up. Conclusion This study is the first to report PD-L1 expression of the heart that can be quantified non-invasively without invasive myocardial biopsy, with high reliability and specificity. This technique can be applied to investigate myocardial PD-L1 expression in ICI-associated myocarditis and cardiomyopathies. Clinical trial registration PD-L1 Expression in Cancer (PECan) study (NCT04436406). ...
